# CARDAMYST (etripamil) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/etripamil

> The FDA approved CARDAMYST (etripamil), sponsored by Milestone Pharmaceuticals Inc. (MIST), on December 12, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is CARDAMYST (etripamil) FDA approved?

Yes. The FDA approved CARDAMYST (etripamil), sponsored by Milestone Pharmaceuticals Inc. (MIST), on December 12, 2025. SEC Form 10-Q: "On December 12, 2025, we announced the FDA approved our first commercial product, CARDAMYST® (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults." [Calendar and source filings](https://sec-api.dev/pdufa/etripamil)

Source: SEC Form 10-Q, accession 0001104659-26-126504, https://www.sec.gov/Archives/edgar/data/1408443/000110465926126504/mist-20260930x10q.htm (retrieved 2026-11-14). Last confirmed 2026-11-13. Cite: https://sec-api.dev/pdufa/etripamil#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | CARDAMYST (etripamil) |
| Codes |  |
| Sponsor | Milestone Pharmaceuticals Inc. (MIST) https://sec-api.dev/companies/mist/catalysts |
| Indications | with paroxysmal supraventricular tachycardia |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2022: topline data readout

- Status: completed, met. Date confidence: month. Stage: 3.
- First seen 2024-11-12, last confirmed 2025-11-12.
- SEC Form 10-Q (accession 0001104659-25-109689): "In October 2022, we announced positive and statistically significant topline efficacy and safety data from the Phase 3 RAPID clinical trial of etripamil in patients with PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "In October 2022, we announced positive and statistically significant topline efficacy and safety data from the Phase 3 RAPID clinical trial of etripamil in patients with PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007648): "In October 2022, we announced positive and statistically significant topline efficacy and safety data from the Phase 3 RAPID clinical trial of etripamil in patients with PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000155837025007648/mist-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-002849): "In October 2022, we announced positive and statistically significant topline efficacy and safety data from the Phase 3 RAPID clinical trial of etripamil in patients with PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000155837025002849/mist-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015147): "In October 2022, we announced positive and statistically significant topline efficacy and safety data from our Phase 3 RAPID clinical trial evaluating etripamil in patients with PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000155837024015147/mist-20240930x10q.htm

### May 2024: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2024-11-12, last confirmed 2025-03-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-023218): "The FDA accepted the NDA for CARDAMYST in May 2024 and has set a Prescription Drug User Fee Act (PDUFA)" https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116493): "The FDA accepted the NDA for CARDAMYST in May 2024 and has set a Prescription Drug User Fee Act (PDUFA)" https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_ex99-1.htm

### May 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2024-11-12, last confirmed 2025-03-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-023218): "The FDA accepted the NDA for CARDAMYST in May 2024 and has set a Prescription Drug User Fee Act (PDUFA)" https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116493): "The FDA accepted the NDA for CARDAMYST in May 2024 and has set a Prescription Drug User Fee Act (PDUFA)" https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_ex99-1.htm

### 1H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116493): "Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in H1 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_ex99-1.htm

### March 27, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2025-03-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-023218): "FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)" https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116493): "NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025" https://www.sec.gov/Archives/edgar/data/1408443/000110465924116493/tm2428099d1_ex99-1.htm
- SEC Form 10-K (accession 0001558370-25-002849): "We expect that the FDA will make their final decision regarding the marketing approval of CARDAMYST for PSVT by March 27, 2025, which is also known as the Prescription Drug User Fee Act, or "PDUFA," review goal date." https://www.sec.gov/Archives/edgar/data/1408443/000155837025002849/mist-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-016929): "User Fee Act ("PDUFA") date of March 27, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925016929/tm257508d1_ex99-1.htm
- SEC Form 10-K (accession 0001558370-25-002849): "The PDUFA goal date for action on the NDA is March 27, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000155837025002849/mist-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-023218): "review goal date for March 27, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925023218/tm259067d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-016929): "Potential approval of CARDAMYST, PDUFA March 27, 2025" https://www.sec.gov/Archives/edgar/data/1408443/000110465925016929/tm257508d1_ex99-1.htm
- SEC Form 10-Q (accession 0001558370-24-015147): "The FDA has informed the Company of a prescription drug user fee act (PDUFA) date of March 27, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000155837024015147/mist-20240930x10q.htm
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218571_20250327.pdf%22

### March 27, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-05-14, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218571_20250327.pdf%22
- SEC Form 10-Q (accession 0001104659-25-109689): "As a result of the Complete Response Letter, or the "CRL," received in March 2025 from the Food and Drug Administration, the Company temporarily paused the ramping up of operational expenditures related to the commercialization of etripamil and is monitoring its cash flows." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109689): "In March 2025, we announced that we received a Complete Response Letter, or "CRL," regarding our New Drug Application, or "NDA," for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109689): "In March 2025, we announced that we received a CRL regarding our NDA for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109689): "In March 2025, we announced that we received a CRL regarding our New Drug Application, or "NDA," for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "As a result of the Complete Response Letter, or the "CRL," received in March 2025 from the Food and Drug Administration, the Company temporarily paused the ramping up of operational expenditures related to launching etripamil and is monitoring its cash flows." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "In March 2025, we announced that we received a Complete Response Letter, or "CRL," regarding our New Drug Application, or "NDA," for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "In March 2025, we announced that we received a CRL regarding our NDA for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "In March 2025, we announced that we received a CRL regarding our New Drug Application, or "NDA," for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC prospectus (424B) (accession 0001104659-25-067502): "In March 2025, we announced that we received a Complete Response Letter, or "CRL," regarding our New Drug Application, or "NDA," for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000110465925067502/tm2520348-3_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-067130): "In March 2025, we announced that we received a Complete Response Letter, or "CRL," regarding our New Drug Application, or "NDA," for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000110465925067130/tm2520348-1_424b5.htm
- SEC Form 10-Q (accession 0001558370-25-007648): "As a result of the Complete Response Letter received in March 2025 from the Food and Drug Administration, the Company has temporarily paused the ramping up of operational expenditures related to launching etripamil and is monitoring its cash flows." https://www.sec.gov/Archives/edgar/data/1408443/000155837025007648/mist-20250331x10q.htm

### June 13, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-08-12, last confirmed 2025-08-12.
- SEC Form 10-Q (accession 0001558370-25-011141): "On June 13, 2025, we submitted our response to the FDA's CRL regarding the NDA for CARDAMYST (etripamil) nasal spray, which was accepted." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm

### June 13, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-08-12, last confirmed 2025-08-12.
- SEC Form 10-Q (accession 0001558370-25-011141): "On June 13, 2025, we submitted our response to the FDA's CRL regarding the NDA for CARDAMYST (etripamil) nasal spray." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm

### July 11, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-07-11, last confirmed 2025-07-14.
- SEC prospectus (424B) (accession 0001104659-25-067502): "On July 11, 2025, we announced that the FDA had accepted our response to the Complete Response Letter regarding our NDA for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000110465925067502/tm2520348-3_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-067130): "On July 11, 2025, we announced that the FDA had accepted our response to the Complete Response Letter regarding our NDA for CARDAMYST (etripamil) nasal spray for the treatment of PSVT." https://www.sec.gov/Archives/edgar/data/1408443/000110465925067130/tm2520348-1_424b5.htm

### July 11, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: with paroxysmal supraventricular tachycardia.
- First seen 2025-08-12, last confirmed 2025-11-12.
- SEC Form 10-Q (accession 0001558370-25-011141): "On July 11, 2025, we announced that the FDA accepted for review our response to issues raised in the CRL for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109689): "Further, on July 11, 2025, we announced that the FDA accepted for review our response to issues raised in the CRL." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "Further, on July 11, 2025, we announced that the FDA accepted for review our response to issues raised in the CRL." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm

### December 12, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-12-15, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-120904): "2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465925120904/tm2533390d1_ex99-2.htm
- SEC Form 10-Q (accession 0001104659-26-126504): "On December 12, 2025, we announced the FDA approved our first commercial product, CARDAMYST® (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926126504/mist-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-126504): "On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST® (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or "PSVT," to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926126504/mist-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-094435): "On December 12, 2025, we announced the FDA approved our first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926094435/mist-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-094435): "On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or "PSVT," to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926094435/mist-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-059752): "On December 12, 2025, we announced the FDA approved our first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926059752/mist-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-059752): "On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or "PSVT," to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926059752/mist-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-032415): "On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT, to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/mist-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-032415): "On December 12, 2025, we announced the FDA approved our first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/mist-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-032415): "On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or "PSVT," to sinus rhythm in adults." https://www.sec.gov/Archives/edgar/data/1408443/000110465926032415/mist-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-032427): "CARDAMYST nasal spray was approved by the FDA on December 12, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/tm269403d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-006483): "U.S. Food and Drug Administration (FDA) approved CARDAMYST on December 12, 2025, marking the first FDA approval of a treatment for PSVT in more than 30 years." https://www.sec.gov/Archives/edgar/data/1408443/000110465926006483/tm263973d1_ex99-1.htm

### December 13, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-07-11, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-076468): "FDA Accepted the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025" https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-067108): "Company issued a press release announcing that the U.S. Food and Drug Administration has accepted for review the Company's response to issues raised in the Complete Response Letter regarding its New Drug Application for CARDAMYST (etripamil) nasal spray for the management of paroxysmal supraventricular tachycardia and assigned a new Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925067108/tm2520348d2_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109744): "A New Drug Application (NDA) for CARDAMYST is currently being reviewed by the U.S. Food and Drug Administration (FDA), with a PDFUA action date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109744/tm2530945d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-076468): "FDA accepted the Company's response to the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) Nasal Spray and set a new Prescription Drug User Fee Act (PDFUA) target date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-067108): "New PDUFA Action Date of December 13, 2025" https://www.sec.gov/Archives/edgar/data/1408443/000110465925067108/tm2520348d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-076468): "CRL and assigned a new PDUFA target date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-067108): "Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925067108/tm2520348d2_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-25-109689): "With the acceptance the FDA issued a Prescription Drug User Fee Act, or "PDUFA," target date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109689): "The FDA has assigned a new PDUFA target date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000110465925109689/mist-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "With the acceptance the FDA issued a Prescription Drug User Fee Act, or "PDUFA," target date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "The FDA has assigned a new PDUFA target date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011141): "In conjunction with the acceptance, the FDA has assigned a new PDUFA target action date of December 13, 2025." https://www.sec.gov/Archives/edgar/data/1408443/000155837025011141/mist-20250630x10q.htm

### March 20, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-03-20, last confirmed 2026-03-20.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-032427): "Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil)" https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/tm269403d1_ex99-1.htm

### 2H 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-05-13, last confirmed 2026-05-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059780): "Company currently expects its cash, cash equivalents and short-term investments to be sufficient to cover operating expenses and capital expenditure into the second half of 2027, including expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as described above." https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_ex99-1.htm

### 2H 2028: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-11-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-126519): "Ongoing Phase 3 pivotal trial (ReVeRA-301) evaluating etripamil nasal spray in atrial fibrillation with rapid ventricular rate (AFib-RVR) is on schedule; topline data expected in the second half of 2028." https://www.sec.gov/Archives/edgar/data/1408443/000110465926126519/tm2629645d1_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/etripamil.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CARDAMYST (etripamil) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/etripamil

```bibtex
@misc{secapidev_pdufa_etripamil_20261116,
  title        = {CARDAMYST (etripamil) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/etripamil}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_etripamil_20261116","title":"CARDAMYST (etripamil) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/etripamil","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
